Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Ajai Chari,Dorothy Romanus,Aditya Raju,Lauren Cain,Marlo Blazer,Eileen Farrelly,Dawn Marie Stull,Sikander Ailawadhi

doi:10.1182/blood-2019-121658

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Ajai Chari, Dorothy Romanus + Show 6 more

Open Access

https://doi.org/10.1182/blood-2019-121658

Copy DOI

Journal: Blood	Publication Date: Nov 13, 2019
Citations: 1

Affiliation: Mayo Clinic, Icahn School of Medicine at Mount Sinai, Takeda (United States), Millennium Engineering and Integration (United States)

#Time To Next Therapy #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Full Text